Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients.
about
Novel rapid-immunohistochemistry using an alternating current electric field for intraoperative diagnosis of sentinel lymph nodes in breast cancer.HER2 expression in fine needle aspirates of lymph nodes detected by preoperative axillary ultrasound in breast cancer patients.MicroRNAs as clinical biomarkers?Biopsy of breast cancer metastases: patient characteristics and survivalEfficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.Comparison of Predictive Immunohistochemical Marker Expression of Primary Breast Cancer and Paired Distant Metastasis using Surgical Material: A Practice-Based StudyTranscriptome sequencing uncovers a three-long noncoding RNA signature in predicting breast cancer survival.Immuno-PET for Clinical Theranostic Approaches.Molecular Concordance Between Primary Breast Cancer and Matched Metastases.Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site.Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer?Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.Cytologic assessment of estrogen receptor, progesterone receptor, and HER2 status in metastatic breast carcinoma.Spatial intratumoural heterogeneity in the expression of GIT1 is associated with poor prognostic outcome in oestrogen receptor positive breast cancer patients with synchronous lymph node metastases.
P2860
Q33765728-692D9563-B562-4D6E-84ED-5C2063F3134DQ34506643-EC8CA6E2-F0E2-41EA-B673-17C6AD26EEBAQ35847902-25771F07-21C8-467F-B8F7-F33FD47C2DBAQ36239768-D56C81F2-62FD-4E86-86D6-556313B15BDCQ36279700-F075C68F-EB8F-4393-B0CF-9A6207BD0FFFQ36756659-5C71C425-E887-4463-82D2-6D2127AE6D8CQ37034875-A73546C2-FC22-49F1-9595-7D27F2A5A971Q37631461-C9B6CDD7-C47C-408A-8D23-529C59E1665EQ38810954-47783460-A197-4180-B288-C08E2D430E0CQ41281294-A992DE05-2CB1-468E-BF13-AB3FF693199CQ47150180-7B2EE161-3CB9-4807-813F-207F86D7A184Q51464606-3E079EA6-C2F9-4ED3-B7BE-A170070330CCQ53277939-BD3A1611-1A86-4413-B952-85A6856FE46BQ54976973-34DDB54E-371B-4902-9924-A37797362E6B
P2860
Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Discordances in ER, PR and HER ...... val in breast cancer patients.
@en
Discordances in ER, PR and HER ...... val in breast cancer patients.
@nl
type
label
Discordances in ER, PR and HER ...... val in breast cancer patients.
@en
Discordances in ER, PR and HER ...... val in breast cancer patients.
@nl
prefLabel
Discordances in ER, PR and HER ...... val in breast cancer patients.
@en
Discordances in ER, PR and HER ...... val in breast cancer patients.
@nl
P2093
P2860
P1433
P1476
Discordances in ER, PR and HER ...... val in breast cancer patients.
@en
P2093
Ning-Fu Peng
Shu-Rui Xie
Yan-Fang Xie
Ying-Yang Liao
Yu-Feng Yang
P2860
P2888
P356
10.1007/S12032-014-0214-2
P577
2014-09-13T00:00:00Z